Editorial comment on: Low-activity V89L variant in SRD5A2 is associated with aggressive
prostate cancer risk: an explanation for the adverse effects observed in chemoprevention …

OBJECTIVE: The 5-alpha-reductase type 2 (5A2) enzyme catalyses the irreversible
conversion of testosterone to dihydrotestosterone, the most active androgen in the prostate …

BACKGROUND Increasing studies investigating the association between steroid 5‐alpha
reductase type II gene polymorphism at codon 89 (SRD5A2 V89L) and susceptibility to …

Abstract 5α-Reductase type 2, the predominant prostatic isozyme of this protein, converts
testosterone to dihydrotestosterone. It has been hypothesized that individuals with greater …

Prostate cancer is a significant cause of death in Western countries and is under the strong
influence of androgens. The steroid 5α-reductase 2 catalyzes the metabolism of testosterone …

Purpose: Common treatments for benign prostatic hyperplasia include 5α-reductase
inhibitors and α-adrenergic receptor antagonists. However, these treatments can only …

Aim De novo androgen synthesis is thought to be involved in the progression to castration-
resistant prostate cancer (CRPC) during androgen-deprivation therapy (ADT). During …

Inhibitors of 5α-reductase (SRD5A) that lower intraprostatic levels of dihydrotestosterone
(DHT) reduce the overall incidence of prostate cancer (PCa), but there is significant variation …

The steroid 5-alpha reductase type II gene (SRD5A2) encodes the enzyme which converts
testosterone (T) to the more active androgen dihydrotestosterone. A non-synonymous single …

It has been suggested that the activity of the steroid 5α-reductase type II enzyme (encoded
by the SRD5A2 gene) may be associated with prostate cancer risk and that population …